Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
Acquired by Johnson &amp; Johnson: In a landmark deal completed on May 31, 2024, Shockwave Medical was acquired by Johnson &amp; Johnson for an enterprise value of approximately $13.1 billion and now operates as a business unit within Johnson &amp; Johnson MedTech. This strategic acquisition integrates Shockwave's innovative technology into a global healthcare leader, significantly altering its operational and strategic outlook.</li>
 <li>
Pioneering Intravascular Lithotripsy (IVL) Technology: Shockwave is the market pioneer and leader in intravascular lithotripsy, a novel, catheter-based therapy that uses sonic pressure waves to safely fracture problematic calcium deposits in arteries. This technology addresses a significant unmet need in treating calcified coronary artery disease (CAD) and peripheral artery disease (PAD), offering a differentiated and safer alternative to traditional methods like high-pressure balloons and atherectomy.</li>
 <li>
Exceptional Financial Growth Track Record: Prior to its acquisition, Shockwave demonstrated a remarkable growth trajectory, transitioning from a pre-revenue company to a profitable enterprise with substantial revenue growth. The company's revenue grew at a 3-year CAGR of 120.85%, showcasing rapid market adoption and strong clinical demand for its products.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Acquired by Johnson &amp; Johnson: In a landmark deal completed on May 31, 2024, Shockwave Medical was acquired by Johnson &amp; Johnson for an enterprise value of approximately $13.1 billion and now operates as a business unit within Johnson &amp; Johnson MedTech. This strategic acquisition integrates Shockwave's innovative technology into a global healthcare leader, significantly altering its operational and strategic outlook.
  
Pioneering Intravascular Lithotripsy (IVL) Technology: Shockwave is the market pioneer and leader in intravascular lithotripsy, a novel, catheter-based therapy that uses sonic pressure waves to safely fracture problematic calcium deposits in arteries. This technology addresses a significant unmet need in treating calcified coronary artery disease (CAD) and peripheral artery disease (PAD), offering a differentiated and safer alternative to traditional methods like high-pressure balloons and atherectomy.
  
Exceptional Financial Growth Track Record: Prior to its acquisition, Shockwave demonstrated a remarkable growth trajectory, transitioning from a pre-revenue company to a profitable enterprise with substantial revenue growth. The company's revenue grew at a 3-year CAGR of 120.85%, showcasing rapid market adoption and strong clinical demand for its products.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Shockwave Medical Inc (SWAV US) - Aug 2026

United States

Shockwave Medical, Inc. manufactures medical devices. The Company offers intravascular devices and balloon dilatation catheters for patients with calcified cardiovascular disease. Shockwave Medical serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Shockwave Medical Inc (SWAV US) - Aug 2026

Acquired by Johnson & Johnson: In a landmark deal completed on May 31, 2024, Shockwave Medical was acquired by Johnson & Johnson for an...

αSK Primers